Medipal Holdings
Medipal Holdings is a Tokyo-based holding company established in 1898, specializing in the distribution of pharmaceuticals, cosmetics, and daily necessities. The company operates through three main segments: prescription pharmaceuticals, cosmetics and over-the-counter (OTC) products, and animal health products. The prescription pharmaceutical segment is the largest revenue generator, supplying hospitals, clinics, and pharmacies with essential medications. The cosmetics and OTC pharmaceutical segments cater to drugstores, convenience stores, and supermarkets, providing a wide range of health and beauty products. Additionally, the animal health segment serves veterinary hospitals and agricultural needs, ensuring a comprehensive approach to health and wellness across various markets.
7 past transactions
Presus Cube
Acquisition in 2024
Presus Cube is a business specializing in pharmacy management support services. It offers data discovery, standardizing pharmacy operations, and survey support to assist clients in informed decision-making and policy creation.
Heartseed
Series C in 2021
Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.
Heartseed
Corporate Round in 2020
Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.
FunPep
Venture Round in 2018
FunPep specializes in the research and development of pharmaceutical products, cosmetics, and medical devices utilizing functional peptides. Its primary focus is on creating innovative treatments for intractable ulcers and exploring next-generation pharmaceutical alternatives to antibody medicines.
Clipla
Venture Round in 2018
Clipla is a healthcare technology company specializing in cloud-based electronic medical records (EMR) systems tailored for hospitals. Their comprehensive suite of products caters to various departments within hospitals, facilitating efficient data capture and storage at minimal installation and maintenance costs. Clipla's solutions aim to streamline workflows for all staff members, including doctors, nurses, and administrative personnel, thereby enhancing overall medical treatment processes.
Scohia Pharma
Venture Round in 2017
Scohia Pharma is a Fujisawa, Japan-based biopharmaceutical company focused on researching, designing, and developing therapies for metabolic, cardiovascular, and renal diseases. Its work targets lifestyle-related conditions such as obesity, diabetes, dyslipidemia, and hypertension, with an emphasis on delivering treatments that improve patient outcomes through research and development across metabolic and renal disorders.
FunPep
Venture Round in 2016
FunPep specializes in the research and development of pharmaceutical products, cosmetics, and medical devices utilizing functional peptides. Its primary focus is on creating innovative treatments for intractable ulcers and exploring next-generation pharmaceutical alternatives to antibody medicines.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.